Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

August 6, 2021

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 52 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. I'm Phyllis, and I'll be serving as your conference operator for today. I'd like to extend a welcome to all of you on this call for Cronos Group's 2021 Second Quarter Earnings Conference Call. This call is being recorded today. Right now, I'll hand things over to Shayne Laidlaw from Investor Relations. Shayne, please go ahead.

Shayne Laidlaw

executive
#2

Thank you, Phyllis, and I appreciate everyone being with us today as we go through Cronos Group's financial and business results for the second quarter of 2021. With me on this call are Kurt Schmidt, our President and CEO; Jerry Barbato, our CFO; Mike Gorenstein, our Executive Chairman; and Xiuming Shum, our EVP of Legal and Regulatory affairs. This morning Cronos Group put out a news release reporting these financial results, and that release is filed on our EDGAR and SEDAR profiles. That information, along with the prepared remarks, will also be available on our website in the Investor Relations section. Before handing the call to Kurt, I want to remind everyone that what we discuss on this conference call will contain forward-looking statements. Those statements rest on assumptions and are subject to risks and uncertainties, and actual results could therefore differ materially from what those forward-looking statements project. This includes as a result of the factors laid out in the cautionary statements and risk factors contained in the company's earnings release and regulatory filings, among them the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and any forward-looking statements made during this call are qualified in their entirety by those documents. Also, during this call, certain financial measures that are not recognized under the U.S.

Shayne Laidlaw

executive
#3

Broadly accepted accounting rules that the Securities and Exchange Commission labels as non-GAAP metrics. In our view, such non-GAAP metrics help management with planning, forecasting, and assessing business and financial performance, including how resources get allocated. You can find reconciliations of these non-GAAP metrics to the nearest reported GAAP metrics in the earnings press release we furnished to the SEC, which sits in the press room area of our website at cronosgroup.com. These non-GAAP metrics might not be comparable to those other issuers use. I'd also like to mention that today's call is being held from our separate remote locations. Because of that, brief delays, cross-talk, or small technical problems may occur during this call. We appreciate your patience and understanding ahead of time. We'll now deliver prepared remarks, and after that we'll shift to a question-and-answer session. With that, I'll hand things over to Cronos Group's President and CEO, Kurt Schmidt.

Kurt Schmidt

executive
#4

Thanks, Shayne. Morning, everybody, and thanks for being with us today. Early this year, it became clear to me how essential an intense emphasis on creating disruptive technology and innovation is for Cronos. During the quarter just ended, we made a significant move toward delivering commercial-scale cultured cannabinoids to the market by amending our Ginkgo Bioworks agreement so that we can speed up commercialization of cultured cannabinoids at scale. Right now, we hold every license required to commercialize a product that uses cultured cannabinoids made at our Winnipeg facility, and later this year in Canada we intend to be first to market with a product tapping this technology. Cultured CBG will be what we use, and that initial product brought to market, made possible through our Ginkgo partnership, and we anticipate the final productivity goal for CBG being reached within the next few weeks, ahead of September 2021, as previously announced. We are taking steps so that Cronos becomes synonymous with innovation. Introducing cultured rare cannabinoids as a wider long-term strategy for branding and product differentiation. It won't be merely one single item featuring CBG. In our view, the Spinach brand is an excellent platform for delivering these rare cannabinoids and unique formulations to our adult consumers.

Kurt Schmidt

executive
#5

There are lots of distinctive compounds in cannabis that could serve a broad variety of purposes and offer various benefits. At Cronos, concentrating on uncommon cannabinoids is going to build substantial marketplace expertise and shopper understanding, which we expect will assist in producing original and inventive offerings. To turn our innovation pipeline into reality, our cross-functional groups have been working hard, creating and commercializing fresh products. We follow a disciplined method for developing products—zeroing in on consumer insights, testing what we make, and pushing ourselves to launch best-in-class items. During the second quarter, under our Spinach brand we introduced SOURZ by Spinach in Canada—a thrilling new range of cannabis gummies featuring bold and distinctive dual fruit flavor pairings. SOURZ by Spinach came from the seasoned crew at Cronos Group made up of professional chefs, food scientists, and consumer packaged goods specialists. I feel proud that the brand could meet the challenge of building a cannabis edible product grounded in the principles of the confectionery category. SOURZ offers bold fruit flavors in a unique S shape, with a proprietary coating engineered to give a sour and sweet taste profile—setting the product apart and lifting the consumer experience. Adult consumers get an unmatched taste from this product, and early reactions to it have been excellent.

Kurt Schmidt

executive
#6

Based on Hifyre numbers, SOURZ by Spinach captured a market share in the double digits within edibles across July and the period through August so far. OCS figures covering Ontario sales made to retailers show that during the 4 weeks ended August 1, 2021, all 3 SKUs under SOURZ by Spinach placed among the top 10 in the edible segment. Capitalizing on how well our Spinach gummies lineup is performing, our intention is to use this brand together with this product format to launch culture CBG into the market. This upcoming Spinach gummies line, made with cultured CBG alongside THC that is traditionally cultivated and extracted, is going to offer the same core differentiators found in our other SKUs, while delivering distinct flavor profiles. The debut Spinach gummy that incorporates cultured CBG is slated for a pineapple star fruit flavor, and the early read from selling efforts looks strong. Spinach also brought out a new concentrate offering named Spinach DABZ in a 28-gram format for Spinach flower known as Spinach Nuggetz in Canada. The Spinach brand keeps expanding into additional categories in order to meet consumer needs and strengthen our presence on dispensary shelves throughout Canada. Together with these exciting entries into new categories, Spinach is shiny within the dry flower category.

Kurt Schmidt

executive
#7

For the 4 weeks that ended on August 1, 2021, the Spinach GMO Cookies 3.5 gram flower SKU landed among the top 5 SKUs. According to OCS data, it held the #1 SKU position across all product formats for multiple weeks. That really stands as proof of everything our cross-functional teams have poured into the brand and the product, and we're now watching that pay off on shelf. Now to the U.S. market. We're excited to formally relaunch our CBD brand, PEACE+, via the direct-to-consumer channel. PEACE+'s first portfolio of CBD tinctures is available now on peaceplus.com, with plenty more exciting new products coming soon. The reason we're relaunching the PEACE+ brand is that, strategically, PEACE+ pairs nicely with our other CBD brands. It also opens up future distribution opportunities for us by making a line of CBD products for mass market consumers in the United States, and it gives us an offering at a mainstream price point. We're eager to see all the further innovation still to come from this brand, and we look forward to reaching another group of adult consumers with this offering. So far we've gotten strong indications of interest in PEACE+ from some significant convenience store chains.

Kurt Schmidt

executive
#8

We also expect to begin shipments into regional test markets before long, which would add to what we are already doing through direct-to-consumer channels. This July, Happy Dance — the masstige brand we cofounded with actress Kristen Bell — introduced a new facial skin care item: a localized CBD face moisturizer. That moisturizer feels light on the skin and contains hydrating ingredients such as avocado oil, hyaluronic acid and premium-quality CBD. U.S. shoppers can buy the product right now online via the brand's direct-to-consumer site, doahappydance.com, as well as on ulta.com. And within the next few weeks, it is expected to reach ULTA Beauty stores across the U.S. Growing our product portfolio remains essential for drawing new consumers to the brand and giving current consumers choices and extra products, enabling them to broaden the occasions on which they use our brand. In the Israeli market, registered cannabis patients keep increasing in number and now approach 100,000. Our PEACE NATURALS brand still connects strongly with consumers in this fast-expanding medical cannabis market. Inside Israel's cannabis market, our dry flower offerings keep delivering solid results, and the oils and pre-rolls we launched recently are building momentum. Now to our people. I'd like to pause for a moment and talk about a new addition to our Board of Directors along with a few important hires, which underscores how committed we are to assembling a winning team of experienced, passionate professionals.

Kurt Schmidt

executive
#9

At our Annual General Meeting, shareholders elected a new member to the Board, Kendrick Ashton. Kendrick serves as Co-Founder and a key Co-Chief Executive Officer of The St. James, which is a leading developer and operator of performance, wellness and lifestyle brands. Prior to starting The St. James, he was a founding member and Managing Director at Perella Weinberg Partners, a financial services firm. The combination of Kendrick's business acumen and entrepreneurial experience makes him a great fit for our Board. I'm happy to welcome Kendrick Ashton to the Cronos Board of Directors, and I look forward to his expertise helping us as an organization. Last month, Carlos Cortez came on board as VP and Controller. Carlos heads our global accounting, shared services, cost accounting and financial reporting team. Carlos brings 18 years of experience with him, including time as a Senior Finance Director for Discovery, Inc. Before his time at Discovery, Carlos spent 5 years as the Corporate Controller for Malibu Boats. This month, we also welcomed Anthony Parisi to Cronos as the new Head of Global Audit. Anthony will lead our efforts to build world-class internal controls by developing top-tier risk management, control and governance profit. Anthony brings over 18 years of audit experience with him.

Kurt Schmidt

executive
#10

And quite recently, the Vice President of Internal Audit at 2 NYSE-listed companies, RPC, Inc. and Marine Products Corporation. And finally, though by no means least, Thomas Cohn came aboard Cronos as Head of Regulatory and Product, a role at Cronos that was newly created. Thomas came to us from The Avon Company, where his title was General Counsel and Corporate Secretary. Thomas also spent 18 years at the Federal Trade Commission, where his responsibilities included, among other things, overseeing any trust and consumer protection investigation as well as law enforcement actions. Kendrick, Carlos, Anthony and Thomas represent just a portion of the talent we have brought in throughout the organization. We are eager to see them, along with the other new team members, help drive the evolution of Cronos as we strive to establish ourselves as a leading cannabinoid company. As noted previously, we have been actively assessing opportunities within the U.S. cannabis market while legalization efforts and the regulatory process keep evolving. With more and more states legalizing cannabis, and with clear momentum toward federal legalization, we want to ensure we have a seat at the table and are well positioned to seize market opportunities at the right moment. In June, we were delighted to announce a strategic investment in PharmaCann, which lays the groundwork for our entry into the U.S.

Kurt Schmidt

executive
#11

Turning to the market. PharmaCann is a top vertically integrated cannabis operator in the U.S., and it has shown real operating skill while holding a strong position in limited-license states that carry high value. Its U.S. geographic footprint is substantial, spanning 6 production facilities plus 24 dispensaries that run under the Verilife brand in 6 states: New York, Illinois, Ohio, Maryland, Pennsylvania and Massachusetts. We're eager about the chance to partner with PharmaCann going forward, since we share a dedication to raising product quality and consistency through science along with best-in-class operations and manufacturing. When it comes to PharmaCann, the investment we've identified satisfies every criterion on our list for a strategic investment: market leader, unique platforms, intellectual property and branding potential. Given its strategic manufacturing infrastructure, its talented product development team and best-in-class operations across multiple high-growth states, we have confidence in what PharmaCann can achieve. Our U.S. growth strategy stays centered on delivering long-term shareholder value by assembling a portfolio of best-in-class brands and intellectual property, while at the same time positioning ourselves to deploy our products in the U.S. market via strategic investments in U.S. leaders that share our vision and commitment to responsibly distribute disruptive cannabinoid products that improve people's lives. We also expect to achieve growth through organic opportunities, drawing on the existing brand and IP developed in-house.

Kurt Schmidt

executive
#12

Also, as mentioned before, our culture cannabinoid capabilities stand out. We're likewise heartened by the thoughtful, serious legislation Senator Schumer, Booker and Wyden have put forward, which offers a degree of restorative justice to the individuals and communities that the war on drugs harmed. It's our strong conviction that policymakers and regulators need to put resources into approaches that back responsible adult consumption and reduce consumer harm by shrinking the illicit market. And establish a legal, well-regulated federal framework for the U.S. cannabis industry. We urge Congress to move quickly and pass the Cannabis Administration and Opportunity Act into law. Beyond reporting our business results today, we announced that Bob Madore has been appointed as our next Chief Financial Officer. Bob officially joins the company on Monday and will succeed Jerry Barbato. Bob is a senior executive bringing more than 30 years of financial and operational experience across a number of well-known global consumer brands. He was CFO at American Eagle Outfitters. Before that, he held a variety of roles of increasing responsibility at Ralph Lauren, among them CFO from 2015 to 2016. He's known for building high-performing teams and delivering outstanding results.

Kurt Schmidt

executive
#13

I'm eager for us to collaborate as we keep carrying out our plan and speed up Cronos's growth. I'd like everyone to help me welcome Bob into his new position. I'd also like to express gratitude to Jerry for what he has given our company across the past 2 years. While Jerry was with Cronos, he was key to the finance and procurement areas, leading the SAP rollout in both Canada and the U.S., and developing our information systems and capabilities with a fresh emphasis on cybersecurity. Speaking personally, he gave me enormous help as I was settling in at Cronos. Working alongside him has been a pleasure, I value his partnership, and I wish him the very best. I'll now hand things over to Jerry so he can offer a few remarks about his announcement before we move into the 2021 second quarter financial results.

Jerry Barbato

executive
#14

Thanks, Kurt, and good morning, everyone. Working with the Cronos team has been a privilege, and I'm proud of everything we've accomplished over the last several years. I know that under Bob's leadership and with the support of the outstanding teams across the organization, the company is well positioned to lead the global cannabis industry and capture the significant opportunities ahead. I will now move to a discussion of our 2021 second quarter financial results. The company reported consolidated net revenue in the second quarter of 2021 of $15.6 million, a 58% increase in the prior year period. Revenue growth year-over-year was primarily driven by the continued growth in the adult-use Canadian cannabis market, and increased sales in the Israeli medical market. Consolidated gross loss for the second quarter of 2021 was $15.8 million, a $12.9 million increase in losses from the second quarter of 2020. The increase in losses versus prior year was primarily driven by an increase in inventory write-downs in the Rest of World segment, which totaled $12 million in the second quarter of 2021 versus $3.1 million in the second quarter of 2020. The impact of strategic price reductions on various adult-use cannabis products in Canada taken in the second half of 2020 as well as start-up costs associated with new product development in the Rest of World segment.

Jerry Barbato

executive
#15

For the second quarter of 2021, adjusted EBITDA loss came to $49.8 million, which marks a $22.8 million rise in losses compared with the second quarter of 2020. That year-over-year loss increase stemmed mainly from a larger gross loss, as explained earlier, plus higher sales and marketing spending tied to brand development in the U.S. segment, along with greater R&D costs, driven by product development spending and work on developing cannabinoid IT within the Rest of World segment. Now to our reporting segments. Within Rest of World, net revenue for the second quarter of 2021 totaled $13.4 million, up 74% from the prior year period. The year-over-year revenue growth came primarily from continued expansion of the adult-use cannabis flower market in Canada and from sales in the Israeli medical cannabis market. For the Rest of World segment, gross loss in the second quarter of 2021 was $16.4 million, a $12.9 million increase in losses versus the second quarter of 2020. That increase in losses compared with the prior year was driven mainly by higher inventory write-downs. Also contributing were the effects of strategic price reductions taken in the second half of 2020 on various adult-use cannabis products in Canada, as well as start-up costs related to new product development.

Jerry Barbato

executive
#16

For the Rest of World segment, adjusted EBITDA loss came to $32.6 million in the second quarter of 2021 — that's $14 million more in losses than the second quarter of 2020. What drove that increase was mainly a bigger gross loss along with higher R&D costs. Now moving to the U.S. segment. Net revenue for the second quarter came in at $2.2 million, with gross profit of $0.6 million, and both were roughly flat compared with the prior year period. Adjusted EBITDA loss for the U.S. segment in the second quarter of 2021 totaled $10.7 million, which is $5.9 million more in losses than the second quarter of 2020. Higher sales and marketing costs tied to brand development were the main driver behind that increase. On an overall basis, Cronos Group posted higher net income compared with the prior year period, driven mainly by the change in fair value of the financial derivative liabilities linked to Altria's investment, which the 10-Q describes in more detail. During the second quarter of 2021, the company booked a noncash gain of $115.2 million tied to the change in fair value of those financial derivative liabilities. Cronos still expects that significant reported earnings volatility may occur, driven mainly by the quarterly fair value adjustments connected to movements in Cronos Group's stock price.

Jerry Barbato

executive
#17

Now, on to the balance sheet. At the close of the quarter, the company had roughly $1.1 billion in cash and short-term investments, a decrease of about $142 million compared with the first quarter of 2021. As a reminder — Kurt mentioned this in his prepared remarks — during the second quarter of 2021 we put approximately $110 million toward acquiring an option for a 10.5 stake in PharmaCann, and that accounted for a meaningful share of the sequential decline in cash and cash equivalents. Capital expenditures came to $2.1 million for the quarter, with that spending concentrated across our global strategic priorities. Our commitment to deploying capital in a disciplined way, and only in ways that fit our strategic priorities, remains firm. I continue to be encouraged by the work our teams are doing globally. With that, I'll hand things over to Kurt for closing remarks ahead of Q&A.

Kurt Schmidt

executive
#18

Thanks, Jerry. Even with the pandemic still causing difficulties, our sector keeps demonstrating its ability to bounce back. In this environment, we keep launching novel, high-quality items in the U.S., Canada, Israel and Germany under our brands. Given our balance sheet, the CBD infrastructure we already have, our strategic investor, and the success and insights we are set to releverage from all other markets, we are confident that we are well positioned to rank among the best-in-class cannabis companies in every market where we compete. With that said, let's open the line for questions.

Operator

operator
#19

<<operator_script>> Our initial question is from Andrew Carter at Stifel.

W. Andrew Carter

analyst
#20

I suppose my question is—and maybe I'm going over the same ground here—about gross margin. It keeps coming in below what we'd hope for. So what signals should we be watching for that would show this line starting to perform better? Will the innovation add to margin? Are you situated with your third-party cost such that it can be profitable? Or do you have the price points right? Any help you can give us on that gross margin line.

Jerry Barbato

executive
#21

Thanks, Andrew. As we see it, we certainly recorded $12 million in inventory write-downs during this quarter, and we keep assessing the competitive environment together with what consumers prefer so that we can drive innovation in our products. That, I believe, is the main factor that pressured our margins this quarter. As Kurt mentioned in his prepared remarks, we are clearly observing green shoots when it comes to our revenue and the innovations we've delivered with GMO Cookies in the flower category and our SOURZ in the edibles. And of course, the Ginkgo cannabis products that we plan to launch later in the year.

W. Andrew Carter

analyst
#22

All right, moving to a second question and shifting topics somewhat. The headset figures we've reviewed have confirmed truly robust results for Spinach in Ontario and Alberta especially. So here's one thing I'd like to ask. We're aware that Canada's supply chain is unpredictable. Given that momentum, are reorders meeting what you anticipated? Can the retailers place repeat orders and receive it from the provinces, and are those provinces then coming to you? Could you walk us through that a bit?

Kurt Schmidt

executive
#23

Absolutely, that's accurate. SOURZ is performing very well for us. Two of our SKUs rank within the top 5, and three sit in the top 10. The early success has been strong, and we're confident in our ability to meet demand. As I mentioned, we weren't the first to bring gummies to market. We took some time to get this right, but the early results speak for themselves when it comes to delivering this high-quality product. That confidence has led us to believe that our first rare cannabinoid launch, with CBG, will fall under the SOURZ brand -- under the Edibles brand.

W. Andrew Carter

analyst
#24

Yes. But what I really want to ask is — I understand the strength. What I’m really asking is whether the supply chain is actually producing reorders at a matching level. Or is it simply more of the same ups and downs, like what we tend to see coming from the supply chain?

Kurt Schmidt

executive
#25

Yeah. Well, we're still in the early stages. But the response from the trade has clearly been excellent. So that's a clear signal that reorders ought to be strong as we draw these consumers into the category and get more of them trying it. And with the marketing efforts we have in place there to educate people about the product. So we're feeling fairly bullish, because the product is performing. I mean, we're hearing very good things that the product is performing, and that's a really encouraging sign for repeat business.

Mike Gorenstein

executive
#26

Mike here, and I'd like to build on that point. In Canada, matters have clearly gotten better now that COVID restrictions are gone. Accordingly, many of those supply chain difficulties you've been told about across the provinces stemmed from lockdowns that were tougher in Canada than in the U.S.

Operator

operator
#27

We move now to Rahul Sarugaser of Raymond James, who has our next question.

Rahul Sarugaser

analyst
#28

Bob, welcome aboard—we're really glad to have you. It's excellent news that Cronos fermentations produced via CBG are going to be part of the Spinach gummies before this year is out, especially since Ginkgo has itself been drawing attention to its partnership with us in connection with its own upcoming public listing. So my first question is: how is the Ginkgo Cronos partnership progressing when it comes to developing further cultured cannabinoids? And when would you expect that expanded portfolio—those fungible molecules—to make its way into Cronos products on shelves in Canada, or possibly even in the U.S.?

Kurt Schmidt

executive
#29

Absolutely. Once more, our approach has been adjusted. During the previous call, we discussed placing emphasis on uncommon cannabinoids. As you can see, we are making headway on our initial one, CBG, with that launch approaching soon. So we feel quite positive that we remain on schedule to deliver these products as time goes on. Again, you have heard us mention how we are meeting the milestone timelines we set for the launch plan. We changed the order to prioritize the rarest first rather than common CBD and THC. And we are genuinely optimistic. You will witness this unfolding across the next 18 to 24 months, with these products becoming available. So once more, it comes down to the strength of this joint venture, the partnership, and the innovation we are generating. We are truly, truly confident. Mike, I am not sure whether you would like to add anything on that, given you have been pivotal in the Ginkgo agreement and process.

Mike Gorenstein

executive
#30

Yeah, absolutely — thanks, and I believe that's correct. You're going to keep seeing cultured cannabinoids from us, particularly the rare ones. With CBG, we're beginning with SOURZ, though you'll also see that extend into additional formats, and things are going really well with Ginkgo. It will work much like our CBG rollout, as you begin to see some of the other rare cannabinoids incorporated into particular formats. After that, based on consumer insights, they'll move into other formats too. So that's simply going to roll out in sequence across the coming couple of months and quarters.

Rahul Sarugaser

analyst
#31

Thanks. We’re definitely looking forward to it. Turning now to the U.S., it’s good to hear that the peace talks have been relaunched. Could you give us any additional detail on how partnering with Altria might help drive penetration, especially in the U.S. c-store channel, and how we ought to think about that adoption ramp?

Kurt Schmidt

executive
#32

Right. So yes, we think adding PEACE+ is a signal. It's a genuinely good piece of a pure pricing strategy. And again, we have 4 tincture SKUs launching. We're beginning on our B2C website. That's going to expand. We're working with c-stores and convenience stores, and we hope to make an announcement on that one in the not-too-distant future. As for Altria, that's certainly value-added that we could have. Now, that would require some things we've discussed previously, as far as getting the FDA to — on the edible side, on the regulatory side. But as you know, as soon as there's clarity there, that leverage point of Altria we can take advantage of immediately.

Operator

operator
#33

The next question is from John Zamparo at CIBC.

John Zamparo

analyst
#34

Let me begin with the Spinach brand too. It really does appear to be gaining additional share, and pricing is definitely one piece of that picture. That said, are there any other strategic changes you could tell us about that have contributed — be it promotions, marketing, retailer engagement, or something on the growing side? I'd simply like to understand what's driving that brand to perform so significantly while most other big brands are relatively flat. And connected to that, do you believe you've landed on the appropriate amount of pricing on expenditure? Or is there further investment still to come?

Kurt Schmidt

executive
#35

Yeah, I'd say it comes down to a mix of factors. Innovation is definitely one obvious engine behind it. We mentioned that with the new flower launch, which is performing extremely well. And there's science underpinning the genetics of that plant. SOURZ, which brings together some really great proprietary elements of that product. But really handling it like confectionery, the way Mondelez does when launching a product. It's a terrific product and carrier. So innovation will be a major contributor here. Stretching the brand into certain spaces will also contribute. We discussed Nuggetz in the 28 gram and DABZ arriving there. So as we complete the portfolio. The second piece is focus. We're intensely focused on the Spinach brand. I'd prefer having one power brand over 28 brands that are each sort of doing something. We believe the Spinach brand connects with consumers. It has strong brand positioning. We put a lot of effort into that. I think much of the blocking and tackling execution is likely the third piece of it, which includes some of that marketing. And those 3 elements, I believe, are genuinely our strength moving forward and will keep being the innovation carrier for us.

Kurt Schmidt

executive
#36

That pipeline is actively in development, and we're staging it as we move forward. Mike already touched on the culture of cannabinoids and where that could potentially go. So we believe this is our power brand. And I would rather have 1 Coca-Cola than 55 different bottled water brands, right? So we're really going to concentrate on that brand. And I think we're seeing that strategy pay off.

John Zamparo

analyst
#37

All right, that's excellent. I appreciate the added detail. My second question concerns the PharmaCann investment. Are you looking into further investments of a similar kind? How would you describe how appealing the M&A landscape in the U.S. looks right now? And how do you approach choosing between targeting brands and targeting operators in cultivation or retail?

Kurt Schmidt

executive
#38

Yes, I’ll start us off, and then I’ll hand it to Mike, since he has really been taking the lead on this venture. First, we believe PharmaCann is an excellent one. We have a set of criteria. We consider what we would want to be involved with, and PharmaCann, I mean, truly met every requirement for us. So it’s a fantastic strategy. They are a best-in-class operator. We’ve discussed before this I-80 strategy they have and limited license states from Illinois to Massachusetts. We believe they have the capacity to grow, organically and through M&A. So it really did meet all those requirements. But we’ve been fairly consistent in saying we’re not done. We look at — our criteria include breadth, geographic beachhead items, but brands are also very important. So it’s not outside the realm of possibility that we may focus on something else that brings a different set to the party. But I will tell you, when we look at it, it has to be complementary to the overall strategy. Mike, you should probably weigh in on this a little bit.

Mike Gorenstein

executive
#39

Absolutely, and thank you, John. The M&A environment is definitely appealing right now. A major consideration for many prospective sellers — something the Schumer bill's interstate commerce wording really brought to the fore — is the possible advantages a partnership could deliver and how circumstances might shift once federal legalization arrives. That lines up closely with how we're evaluating things. Brands will definitely matter. In the end, we believe that's where value migrates over the long run. We recognize there's a trade-off between where value moves long-term in brands and, roughly across the medium term, how those brands get built and brought to market. So I'd say similar structures could be possible. There are other structures we've examined as well. Even so, we remain very, very enthusiastic, and we see plenty of appealing opportunities that would suit us nicely in the U.S.

Operator

operator
#40

The following question is from Vivien Azer at Cowen.

Vivien Azer

analyst
#41

Regarding the U.S., I was hoping we might dig a bit deeper into CBD. I wanted to hear your latest view on the market when it comes to sizing. Then, specifically on Happy Dance, could you speak to any trends within the quarter and whether you're seeing any recovery or lift at all as consumers return and are even able to head back into stores?

Kurt Schmidt

executive
#42

Yes, I'll start us off, and then Jerry or Mike can weigh in. We're beginning to see — we had high hopes for recovery from COVID. But as you're aware, recently we appear to be sliding back into this COVID delta situation. So how that will play out is uncertain to us. We felt hopeful, since you are seeing bricks and mortar return, but we need to see that infinite. I must say, on the whole, we aren't pleased with how things stand in the U.S. CBD market. We don't provide a brand-level breakdown of our performance. However, we're conducting a strategic review of the brands. There are some positive elements, but I'm certainly not pleased. I want to see quicker growth. So we're essentially examining everything here. That covers the portfolio, price gap, price management, our approach there, product offerings, and we're reviewing the marketing mix. We don't yet have the complete results. We're working — we're attempting to finish that, but we have a couple — there are 2 markets where we've been testing, advertising with a more aggressive marketing mix on the product. That now appears encouraging, but we need to see how it ultimately turns out.

Kurt Schmidt

executive
#43

Still, we have to go through all of it and confirm we can achieve the pace, since, broadly speaking, this quarter's results did not please us. Yet once more, part of that ties to COVID. Part of it ties to certain shifts in some of the DC capability, particularly with Apple's new security, which has certainly had an impact. Yet again, we believe we get the elements right and we get the investment right. The brand resonates very well with consumers, and we'll get it back to the trajectory we want.

Vivien Azer

analyst
#44

All right, great. Staying focused only on the U.S. for my follow-up, if you don't mind, regarding PharmaCann. Is there anything you're able to say about possible chances involving exchanges or sharing of IP or trademarks?

Kurt Schmidt

executive
#45

Yes. I’ll have Mike address this since his perspective is valuable. He is also the attorney here with me. Yes, we are examining those kinds of matters, but every one of them must be handled within the framework of an investment path and the absence of federal legalization. Still, if you look at what we announced, there is enormous opportunity once federal legalization occurs. That said, it does not mean we aren’t considering what could happen if, before federal legalization, a number of developments take place. I simply cannot make any commitment, because we face that constraint of making sure we can pursue this and pursue it in a manner that makes sense for us and for the regulatory environment. Mike, I don’t know whether you would like to add anything to that.

Mike Gorenstein

executive
#46

Yes, absolutely. Vivien, we definitely view this as quite strategic for us when it comes to getting brands out there. I think the way we really concentrated on securing that edge was through establishing distribution agreements that we can more or less activate at our own discretion. So we'll keep watching things and making sure that whatever steps we take to get our brands out are done in a manner that, from our perspective, wouldn't impact anything with the CSA. But we believe there's a solid partnership we can draw on to leverage brands. Still too early to discuss any trademark swaps that might be imminent, though.

Operator

operator
#47

The following question is from Tamy Chen at BMO Capital Markets.

Tamy Chen

analyst
#48

Starting with the vape segment — I remember some processes from roughly 2 years back. You mentioned that your first rollout of vape items in Canada would be, in a sense, first-gen. Yet you also said you'd be developing next-gen proprietary offerings in that segment. So I just wanted to check whether I could get an update on how that effort is progressing, specifically regarding the innovation work for the vape segment.

Kurt Schmidt

executive
#49

Yes, Kirk here — I appreciate the question. Yes, we're actively working on that, and you'll see something before long. That said, I'd rather not get into specific dates or any innovation details. But we're focused on the vape segment at this moment.

Tamy Chen

analyst
#50

All right, understood. My follow-up question returns to the first culture CBG product that's coming under the flowers format in Canada later this year. I'd like to hear a little about how you plan to position that product. I assume that means from a marketing standpoint, plus making sure store staff are educated about the differentiation so they can convey it to consumers, since that matters with respect to product launches generally in Canada. I realize this is a unique product, but the market is very crowded. Shelves carry a lot of different products and brands. How confident are you that there will be strong uptake for a CBG product specifically? And what kind of work are you doing to ensure it gets the shelf space, gets the bartender attention, and gets the positioning?

Kurt Schmidt

executive
#51

Yes. That's a great question. So, we've got a complete team in place—everyone from the developers and innovation folks to the research we've completed, through to the product developers and the marketing teams. This isn't something we see as a product. We see it as a concept—a business concept. And we think we've got something genuinely interesting here: a sub-brand sitting under the Spinach line. And we believe that's the right approach. That's where my background comes from. Blue Buffalo grew a $1 billion business on one single brand, Blue Buffalo, but we had Life Protection. We had Wilderness. We had the Freedom sub-brand within Blue Buffalo, and we had Basics in there too. And we believe this concept—and we've put a lot of work into figuring out how to communicate with consumers. So obviously, we're rolling out. We have to get to each one of these rare cannabinoids. So it takes time. You can't make all 6 at once. But we aren't thinking about this as a product. This is not a product. This is a brand concept, a lifestyle, positioned against consumers, resonating with consumers. And that's how we look at this thing. And we're confident we're on the road to creating that. And we think that's really what this whole thing is about.

Mike Gorenstein

executive
#52

And Tamy, just to add on that point — if you look at edibles as a crowded category, even setting aside rare cannabinoids, that's exactly where we've noticed a lot of enthusiasm coming from retailers as well as the provincial boards. We brought out Spinach SOURZ and saw immediate strong results, and we viewed that launch as pre-seeding the rare cannabinoid edible. So we've done very well even without them, and we anticipate things will get even stronger once that key differentiator is incorporated into those products.

Kurt Schmidt

executive
#53

To echo what Mike mentioned, we intend to expand the business. Edible gives us a strong beginning, yet additional 2.0 products serve as excellent vehicles for that expansion. As a result, we have innovation on the concept side. We also have innovation in terms of how we can extend the brand into the products as well. So it is an exciting — I believe, as I mentioned, the teams have put in an enormous amount of work. And I believe we have it. And I am eager for — you will begin to see a bit of that once we launch the first one here in September.

Operator

operator
#54

Heather Balsky from Bank of America has our next question.

Heather Balsky

analyst
#55

I'm just wondering, circling back to one of those questions near the start of the Q&A about gross margins. What do you figure has to happen? What kind of scale, and what other, maybe mix shift, I guess, do you need in order to return to a positive gross margin?

Jerry Barbato

executive
#56

Yes. Thank you for asking that, Heather. In the U.S. segment, the key really is pushing that revenue growth. Our revenue declined slightly during this quarter. And I believe that as revenue rises, the margin in that segment will improve. On the Canada side, we're seeing some encouraging momentum with the Spinach brand. And as I mentioned before, our margins took a negative hit this quarter, largely because of the ongoing development of innovative products. So we have some elevated start-up costs at our manufacturing facility. Beyond that, we're up against the price cuts we implemented in the Canadian market during the second half of 2020, and that accounts for part of the impact on a year-over-year basis.

Operator

operator
#57

Bill Kirk from MKM has the next question on the line.

Bill Kirk

analyst
#58

I'd like to return to innovation, though approach it from a somewhat more philosophical angle. The pace seems to have picked up quite dramatically. So, philosophically speaking, what has driven your strategic shift toward concentrating, it appears, with greater urgency on innovation for recreational use?

Kurt Schmidt

executive
#59

Well, appreciate the question. I don’t really see it as a shift. What I mean is, innovation is what we focus on, and we approach it in a very disciplined way to make sure we have a clear point of difference. And at times that just takes longer. Edible is a perfect illustration, I think. We could have just pushed anything out the door. But we considered it from the consumer angle, from the product build angle of what we’re trying to accomplish. And some of that does take more time. With the cultured cannabinoids case, that is a fairly substantial project. That’s essentially new science. When I’m sitting in the Ginkgo meetings, and I’m an undergrad in chemistry, sometimes I need the Head of Innovation to give me a bit of tutoring afterward on some of it. So we are working on some basic technologies. We want bigger ideas. Those tend to take longer. On the other hand, once the system is in place, you can begin to move faster. Once the fundamental building blocks are in place across marketing, the product development teams and the research side, you start to go, and much of that was built. So I think we’re now at the point where we have the right machinery and people to get this done.

Kurt Schmidt

executive
#60

But our view, once more, is that what matters most for us is turning into a branded player — one that delivers excellent products which delight consumers, along with platforms that are both new and distinctive. That is what we stand for. And that emphasis on innovation will not be lost. To us as a company, I think that is genuinely essential.

Mike Gorenstein

executive
#61

Yes. Bill, I believe what you're observing is a considerable amount of effort on our part — and the urgency around product development isn't coming from us. At this point, we have a fair number of products that we've already developed, and we're being very careful about how we launch them. But having a supply chain in place matters. And now that retail is opening back up in Canada, we feel the timing is good.

Operator

operator
#62

Howard Penney from Hedgeye has the next question.

Howard Penney

analyst
#63

Could you go into more detail about the PharmaCann investment—specifically the commercialization and distribution agreement you signed, and why that matters as you look toward entering the U.S.?

Kurt Schmidt

executive
#64

Alright, I'll start us off, and then Mike is welcome to chime in. Right — this is a long-term commitment for us. This isn't simply a financial investment on our part. What we're aiming to do is build a partnership, and that partnership covers a range of things, including access for our brands and distribution. And access, eventually, for our technologies as well. We have an excellent — and speaking for myself, I genuinely like the people there. Our relationship with PharmaCann is a strong one. We truly see things the same way. And we're genuinely working to build for the long term toward this question: can we create a leading cannabis company in the U.S.? So on all of those fronts, we want to share mutually what we excel at and what they bring, so that we can really push this forward. That's exactly why certain of these commercial terms and distribution terms matter so much to us. Once more, we would love to go faster, but clearly, given the regulatory environment, some matters have to proceed at a different pace. Still, we want commitment, because we view this — despite holding only 10%, we did not enter this as an investment.

Kurt Schmidt

executive
#65

We entered into this as a partnership for the long haul. It's going to help move both of our businesses forward. Mike, I'm not sure whether you'd like to add anything there.

Mike Gorenstein

executive
#66

Thanks. Yeah, I believe that's accurate. There are 2 things driving value here, in our view. First, we think their core business is excellent. So we like this investment purely as an investment, but the second point is that it's really important — depending on how the regulatory landscape takes shape and how things develop in those key restrictive retail markets — like New York, for instance, where there are currently 10 licenses — just knowing we have a trusted partner with a close relationship through which we can launch our disruptive products. That's something that genuinely excites us right now, to keep investing behind innovation, knowing we'll be able to reach consumers exactly when we need to.

Operator

operator
#67

That brings us to the end of the Q&A — we have no more questions at this point. Everyone, today's conference call is now finished. Thanks for joining us. You can go ahead and disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.